Outsourcing integrated drug development programmes is potentially a highly effective and efficient way to advance therapeutics. Putting one contract development and manufacturing organisation (CDMO) in charge of all tasks can enable the seamless progress of programmes and ensure a hassle-free outsourcing experience. However, anecdotal evidence of occasional failures points to the need to have a well-defined strategy.
To gain insight into perceptions of differing outsourcing strategies, Syngene and Pharma Intelligence surveyed industry leaders about their experiences. This free white paper analyses the results of the survey.
Thank you.Please check your email to download the white paper.